Spettel Kathrin, Kriz Richard, Wu Christine, Achter Lukas, Schmid Stefan, Galazka Sonia, Selitsch Brigitte, Camp Iris, Makristathis Athanasios, Lagler Heimo, Willinger Birgit
Division of Clinical Microbiology, Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria.
J Fungi (Basel). 2023 Jan 17;9(2):129. doi: 10.3390/jof9020129.
is a novel and emerging pathogenic yeast which represents a serious global health threat. Since its first description in Japan 2009, it has been associated with large hospital outbreaks all over the world and is often resistant to more than one antifungal drug class. To date, five isolates have been detected in Austria. Morphological characterization and antifungal susceptibility profiles against echinocandins, azoles, polyenes and pyrimidines, as well as the new antifungals ibrexafungerp and manogepix, were determined. In order to assess pathogenicity of these isolates, an infection model in was performed and whole genome sequencing (WGS) analysis was conducted to determine the phylogeographic origin. We could characterize four isolates as South Asian clade I and one isolate as African clade III. All of them had elevated minimal inhibitory concentrations to at least two different antifungal classes. The new antifungal manogepix showed high in vitro efficacy against all five isolates. One isolate, belonging to the African clade III, showed an aggregating phenotype, while the other isolates belonging to South Asian clade I were non-aggregating. In the infection model, the isolate belonging to African clade III exhibited the lowest in vivo pathogenicity. As the occurrence of increases globally, it is important to raise awareness to prevent transmission and hospital outbreaks.
是一种新型且正在出现的致病性酵母，对全球健康构成严重威胁。自2009年在日本首次被描述以来，它已与世界各地的大型医院暴发相关联，并且常常对不止一类抗真菌药物耐药。迄今为止，奥地利已检测到五株该菌。对其进行了形态学特征分析以及针对棘白菌素类、唑类、多烯类和嘧啶类药物，以及新型抗真菌药物ibrexafungerp和manogepix的抗真菌药敏谱分析。为了评估这些分离株的致病性，在[具体动物]中进行了感染模型实验，并开展了全基因组测序（WGS）分析以确定系统地理起源。我们可以将四株分离株鉴定为南亚分支I，一株分离株鉴定为非洲分支III。所有分离株对至少两种不同抗真菌药物类别的最低抑菌浓度均升高。新型抗真菌药物manogepix对所有五株分离株均显示出较高的体外疗效。一株属于非洲分支III的分离株表现出聚集表型，而其他属于南亚分支I的分离株则不聚集。在[具体动物]感染模型中，属于非洲分支III的分离株体内致病性最低。随着[该菌名称]在全球的出现增加，提高认识以预防传播和医院暴发非常重要。
